| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 365 (9472), 1687-1717, 2005 | 7929 | 2005 |
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. M Clarke, R Collins, S Darby, C Davies, P Elphinstone, E Evans, ... Lancet 366 (9503), 2087, 2005 | 6321 | 2005 |
| Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 351 (9114), 1451-1467, 1998 | 4174 | 1998 |
| Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 … S Darby, P McGale, C Correa, C Taylor, R Arriagada, M Clarke, D Cutter, ... Lancet 378 (9804), 1707, 2011 | 4011 | 2011 |
| Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women EARLY Breast Cancer TRIALISTS'Collaborative Group The Lancet 339 (8784), 1-15, 1992 | 3279* | 1992 |
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer A Howell, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, ... Lancet 365 (9453), 60-62, 2005 | 3113 | 2005 |
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC … A Howell, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, ... Lancet 359, 2131-2139, 2005 | 2683* | 2005 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. R Peto, C Davies, J Godwin, R Gray, HC Pan, M Clarke, D Cutter, S Darby, ... Lancet 379 (9814), 432, 2012 | 2285 | 2012 |
| Polychemotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 352 (9132), 930-942, 1998 | 2160 | 1998 |
| Adjuvant docetaxel for node-positive breast cancer M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ... New England Journal of Medicine 352 (22), 2302-2313, 2005 | 1354 | 2005 |
| Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials Early Breast Cancer Trialists’ Collaborative Group N Engl j med 333 (22), 1444-1455, 1995 | 1252 | 1995 |
| Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind … LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ... Cancer journal (Sudbury, Mass.) 7 (5), 377-387, 2001 | 1223 | 2001 |
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial J Cuzick, I Sestak, M Baum, A Buzdar, A Howell, M Dowsett, JF Forbes The lancet oncology 11 (12), 1135-1141, 2010 | 1166 | 2010 |
| Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or … LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 1118 | 2003 |
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial T Arimidex The lancet oncology 9 (1), 45-53, 2008 | 1112 | 2008 |
| The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women MN Harvie, M Pegington, MP Mattson, J Frystyk, B Dillon, G Evans, ... International journal of obesity 35 (5), 714-727, 2011 | 1096 | 2011 |
| Polygenic risk scores for prediction of breast cancer and breast cancer subtypes N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ... The American Journal of Human Genetics 104 (1), 21-34, 2019 | 1018 | 2019 |
| First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, ... Lancet (London, England) 360 (9336), 817-824, 2002 | 898 | 2002 |
| Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the … J Cuzick, M Dowsett, S Pineda, C Wale, J Salter, E Quinn, L Zabaglo, ... Journal of Clinical Oncology 29 (32), 4273-4278, 2011 | 897 | 2011 |
| Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment A Howell, JFR Robertson, J Quaresma Albano, A Aschermannova, ... Journal of Clinical Oncology 20 (16), 3396-3403, 2002 | 877 | 2002 |
Evans DG*, Evans G*University of Manchesterایمیل تأیید شده در mft.nhs.uk